AbCellera Biologics Sees Unusually Large Options Volume (NASDAQ:ABCL)

AbCellera Biologics Inc. (NASDAQ:ABCL) was the target of unusually large options trading activity on Monday. Investors bought 9,236 call options on the company. This is an increase of approximately 93% compared to the typical daily volume of 4,779 call options.

Wall Street Analyst Weigh In

Several analysts have issued reports on ABCL shares. Wall Street Zen lowered shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AbCellera Biologics in a research note on Monday, April 20th. JonesTrading started coverage on AbCellera Biologics in a research report on Friday, April 10th. They issued a “buy” rating and a $11.00 target price for the company. Finally, Cantor Fitzgerald started coverage on AbCellera Biologics in a report on Tuesday, May 5th. They issued an “overweight” rating and a $7.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $7.80.

Institutional Trading of AbCellera Biologics

A number of large investors have recently bought and sold shares of ABCL. Invesco Ltd. increased its position in AbCellera Biologics by 114.6% during the 1st quarter. Invesco Ltd. now owns 24,146 shares of the company’s stock worth $54,000 after purchasing an additional 12,893 shares in the last quarter. Geode Capital Management LLC grew its holdings in AbCellera Biologics by 3.5% during the second quarter. Geode Capital Management LLC now owns 363,188 shares of the company’s stock worth $1,246,000 after acquiring an additional 12,301 shares during the period. Creative Planning lifted its holdings in AbCellera Biologics by 6.9% in the 2nd quarter. Creative Planning now owns 41,003 shares of the company’s stock valued at $141,000 after acquiring an additional 2,656 shares during the last quarter. Raymond James Financial Inc. boosted its position in shares of AbCellera Biologics by 17.0% during the 2nd quarter. Raymond James Financial Inc. now owns 28,049 shares of the company’s stock valued at $96,000 after purchasing an additional 4,070 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of AbCellera Biologics by 1,304.5% in the 2nd quarter. Bank of America Corp DE now owns 224,365 shares of the company’s stock worth $770,000 after purchasing an additional 208,390 shares during the last quarter. Institutional investors and hedge funds own 61.42% of the company’s stock.

AbCellera Biologics Stock Performance

Shares of NASDAQ:ABCL traded up $0.70 during midday trading on Monday, reaching $8.09. 11,636,630 shares of the company’s stock traded hands, compared to its average volume of 5,681,601. AbCellera Biologics has a one year low of $2.74 and a one year high of $8.42. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -16.82 and a beta of 1.17. The stock has a 50 day moving average of $5.07 and a 200 day moving average of $4.11.

AbCellera Biologics (NASDAQ:ABCL) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.08. AbCellera Biologics had a negative net margin of 181.75% and a negative return on equity of 14.86%. The company had revenue of $8.31 million for the quarter, compared to the consensus estimate of $5.41 million. During the same quarter last year, the firm posted ($0.15) earnings per share. Sell-side analysts predict that AbCellera Biologics will post -0.67 EPS for the current fiscal year.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.